6505--RX - PYLARIFY (PIFLUFOLASTAT F 18 INJECTION) Brand name or Equal

The Department of Veterans Affairs Veterans Integrated Service Network 2 is soliciting offers for Pylarify (Piflufolastat F 18 Injection), a radiopharmaceutical product approved by the FDA for medical imaging purposes. This is a brand name or equal solicitation under Request for Quotation number 36C24226Q0246, with the contracting officer being Aleta Jennette at the James J. Peters VA Medical Center in Bronx, New York. Key contract requirements include Nuclear Regulatory Commission licensing, FDA approval, radiochemical purity of at least 95%, minimum sensitivity of 85%, specific activity of at least 1000 mCi/mol, compliance with USP 797 standards, quality control documentation, and on-time delivery performance exceeding 95% with penalties for missed deliveries. The contractor must provide sales representatives, maintain 24/7 emergency ordering capability, supply Material Safety Data Sheets and package inserts, and accept returns for credit under specified conditions. Sealed offers were due on March 12, 2026, at 10:00 AM Eastern Time, with the contract period running from April 1, 2026, through March 31, 2027, on a firm-fixed-price basis.

This procurement is designated as a 100% total small business set-aside. The government seeks delivery of 9.0 millicurie dose injections totaling 930 doses across four VA Medical Centers: James J. Peters (270 doses), East Orange, NJ (200 doses), New York Harbor Brooklyn (320 doses), and Northport (140 doses). All deliveries must occur Monday through Friday before noon to designated nuclear medicine hot labs at each facility. While no specific award value is disclosed in the solicitation documents, the contract represents a 12-month supply commitment with payment made via government purchase credit card within 30 days of acceptance. The places of performance encompass multiple VA Medical Centers across the Veterans Integrated Service Network 2 in the New York/New Jersey region.